Session information

Tweet

Symposium

[S-2] S-2: TDM for the management of cancer therapy

Mon. Sep 25, 2017 10:30 AM - 12:00 PM Main Hall (1F)

Chairs: William Clarke, USA / Yuichi Ando, Japan

+Add all to schedule

[S-2-1] Benefit of TDM depends on therapeutic class of anticancer drugs

Etienne Chatelut (Institut Universitaire du Cancer de Toulouse)

[S-2-2] Exposure-response and pharmacogenomics of tyrosine kinase inhibitors

Tomohiro Terada (Shiga University of Medical Science Hospital)

[S-2-3] Optimization of CML therapy using TDM

Naoto Takahashi (Akita University)